Research programme: GlyTag fusion proteins - GlyTag
Alternative Names: GlyB4; GlyTagsLatest Information Update: 16 Jul 2016
At a glance
- Originator GlyTag LLC; Wayne State University School of Medicine
- Class Recombinant fusion proteins
- Mechanism of Action Epidermal growth factor inhibitors; Epidermal growth factor receptor antagonists; Intercellular signalling peptide and protein inhibitors; Intercellular signalling peptide and protein stimulants; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Injection)
- 17 Feb 2005 This programme is available for licensing worldwide (http://www.glytag.com)